<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5762">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03031938</url>
  </required_header>
  <id_info>
    <org_study_id>A4091065</org_study_id>
    <secondary_id>2013-002548-10</secondary_id>
    <secondary_id>INFANT SAFETY FOLLOW-UP #2</secondary_id>
    <nct_id>NCT03031938</nct_id>
  </id_info>
  <brief_title>Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies</brief_title>
  <official_title>A Protocol To Monitor From Birth To Age 15 Months The Neurological Development Of Infants With Exposure In-utero In Tanezumab Clinical Studies At All Investigational Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A4091065 is a multicenter, prospective, cohort study with enhance physical an
      neurodevelopmental surveillance to characterize the outcomes related to the development of
      infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or
      comparator via maternal exposure or in utero in any tanezumb study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A4091065 is a long term observational follow up study of subjects from tanezumab
      interventional studies A4091056, A4091057, A4091058, A4091059, A4091061 or A4091063
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Physical measures</measure>
    <time_frame>0-2 months, 8 months, 15 months and unscheduled visits up to 36 months</time_frame>
    <description>Occipital-frontal head circumference, length, weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital Signs</measure>
    <time_frame>0-2 months, 8 months, 15 months, unscheduled visits up to 36 months</time_frame>
    <description>Blood pressure, pulse rate, respiratory rate, temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Neurological measures</measure>
    <time_frame>0-2 months, 8 months, 15 months, unscheduled visits up to 36 months</time_frame>
    <description>Mental status, cranial nerves, motor and sensory systems, reflexes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bayley Infant Neurodevelopmental Screener (BINS)</measure>
    <time_frame>8 months, 15 months, unscheduled visits up to 36 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bzoch-League Receptive Expressive Emergent Language Test (REEL-3)</measure>
    <time_frame>8 months, 15 months, unscheduled visits up to 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Cancer Pain</condition>
  <condition>Recurrent Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Long term observational study of subjects from tanezumab parent study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigational medical product (IMP) administered in parent study</intervention_name>
    <description>IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an infant born to a mother who was exposed to study drug on a tanezumab
             clinical study.

          -  The infant's mother (who was the tanezumab clinical study participant) must review,
             agree and sign an informed consent document explaining the details of the perinatal
             and post natal follow up. Where local regulations mandate, the male parent would also
             review and sign the informed consent.

          -  Parents or legal guardian must be willing and able to comply with scheduled visits
             and study procedures.

        Exclusion Criteria:

          -  There are no exclusion criteria for participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091065</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091065&amp;StudyName=Protocol+To+Monitor+The+Neurological+Development+Of+Infants+With+Exposure+In-utero+From+Birth+To+Aged+15+Months+In+Tanezumab+Clinical+Studies</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091065&amp;StudyName=A+Protocol+To+Monitor+From+Birth+To+Age+15+Months+The+Neurological+Development+Of+Infants+With+Exposure+In-utero+In+Tanezumab+Clinical+Studies+At+All+Investigational+Sites</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>January 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exposure in utero in tanezumab program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
